Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer
Autor: | Selena J. An, Emilie D. Duchesneau, Paula D. Strassle, Katherine Reeder-Hayes, Kristalyn K. Gallagher, David W. Ollila, Stephanie M. Downs-Canner, Philip M. Spanheimer |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022) |
Druh dokumentu: | article |
ISSN: | 2374-4677 13741640 |
DOI: | 10.1038/s41523-022-00433-x |
Popis: | Abstract Women with small HER2+ breast cancers may have excellent prognosis with adjuvant single-agent chemotherapy and HER2-targeted therapy. The role of de-escalated therapy in the neoadjuvant setting, however, remains uncertain. We conducted a cohort study of adult women with T1-2/cN0 HER2+ breast cancer diagnosed 2013–2016 in the National Cancer Database treated with neoadjuvant chemotherapy (NAC) and HER2-targeted therapy. Factors associated with pathologic complete response (pCR) and overall survival were examined. In total, 6994 patients were included, 32% cT1 and 68% cT2. Multi-agent NAC was given to 90% of women while single-agent NAC was given to 10% of women. pCR was achieved in 46% of cT2 patients and 43% of cT1, and in 46% of patients treated with multi-agent versus 38% single agent. Patients receiving multi-agent chemotherapy were younger, had fewer comorbidities, and had higher cT stage and grade. In all patients, pCR was associated with improved survival (p |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |